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Abstract 
We describe a 75-year-old Japanese woman with blastic plasmacytoid dendritic cell 
neoplasm. On her first visit, there were multiple areas of disseminated, elastic hard nodules 
with multicentric purpura on her scalp. Histopathologically, there were atypical large 
lymphocytes densely infiltrated through the upper dermis to subcutaneous tissue. 
Immunohistochemical staining revealed that these infiltrated lymphocytes were CD4, CD56 
and vimentin positive. Although we administered several courses of intensive chemotherapy 
soon after the diagnosis, the patient died 5 months after the first visit. 
 
Introduction 
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is recognized as an 
independent entity in the World Health Organization (WHO) 2008 classification for 
tumors of hematopoietic and lymphoid tissues [1] and is thought to be derived from the 
precursors of plasmacytoid dendritic cells [2]. Recently, several reports suggested that, 
in patients with BPDCN, the skin is the first organ to become clinically involved. Indeed, 
various clinical features of the skin area have been reported [2–4]. Typically, the 
involved skin areas of BPDCN are described as showing solitary or multifocal bruise-
like papules, nodules or plaques [2]. Moreover, BPDCN clinically mimicking cutaneous 
lupus erythematosus has also been reported [5]. The disease consistently runs an 
aggressive course and most patients die within the first year after the diagnosis is 
established [3]. Because previous reports indicate that early chemotherapy might show 
a temporary effect in some rare patients and even prolong the survival rate, the 
accurate and rapid diagnosis for this disease is indispensable [3, 4].  
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Case Report 
A 75-year-old Japanese woman visited us with a one-month history of nodules developing on her 
scalp. On her first visit to our hospital, physical examination disclosed multiple areas of disseminated, 
elastic hard nodules with multicentric purpura on her scalp (fig. 1). Histopathologically, there were 
atypical large lymphocytes densely infiltrated through the upper dermis to subcutaneous tissue with 
minimal involvement of the overlying epidermis (fig. 2a). Immunohistochemical staining revealed 
that these infiltrated lymphocytes were CD4, CD56 (fig. 2c, d) and vimentin positive, CD3, CD5, CD7, 
CD8 and CD20 negative. Flow cytometry of the bone marrow lymphocytes revealed cellular 
characteristics as follows: CD4+, CD56+, CD1–, CD2–, CD3–, CD5–, CD7–, CD8–, CD10–, CD14–, CD19–, 
CD20–, CD33–, CD34–. From the above data, we diagnosed this patient as having blastic plasmacytoid 
dendritic cell neoplasm. We first administered THP-COP therapy (pirarubicin, cyclophosphamide, 
oncovin and prednisone). After this intensive chemotherapy, the nodules on the scalp regressed 
temporarily; however, two weeks later, the tumors were rapidly increasing. Thus, we selected A-
Triplev therapy (cytarabine, etoposide, vincristine and vinblastine) and DeVIC therapy (carboplatin, 
ifosfamide, etoposide, dexamethasone) but there was no effect on the tumor growth. Four months 
after the administration of intensive chemotherapy, the patient died before restarting chemotherapy. 
Discussion 
We describe a case of BPDCN on the scalp. Cutaneous involvement is often the first 
manifestation of this disorder, and the lesions have specific features, presenting as 
solitary or multifocal bruise-like nodules and plaques [6]. Thus, dermatologists need to 
be familiar with its clinical features and prognosis. 
BPDCN is a rare and highly aggressive lymphoma. It was formally known as blastic 
natural killer (NK) lymphoma, or agranular CD4+CD56+ hematodermic neoplasm, and 
accounts for about 0.7% of all skin and primary malignant lymphoma [7]. The etiology 
of BPDCN is still unclear. The main clinical features of BPDCN are infiltration of the skin 
and subsequent involvement of bone marrow and lymph nodes. Its typical pathologic 
characteristics are uniformly distributed, dense, medium-sized lymphocytes in the 
dermis layer. Tumor cells are similar in appearance, with a medium-sized, round, or 
irregular nucleus, and the nucleolus is not obvious [6, 7]. Typical 
immunohistochemistry results include positive for CD4, CD56, negative for CD3, CD20, 
myeloperoxidase, and CD33. This type of lymphoma is highly aggressive and most 
patients with BPDCN die within a short period of time after diagnosis [4, 8]. 
Conventional chemotherapy is ineffective. Although early chemotherapy may show a 
temporary effect in some rare patients, the disease often recurs soon afterward [4]. 
Early intensive chemotherapy may yield a better outcome [3, 4]. However, the chance 
of post-treatment recurrence is much higher than with other malignant lymphomas. 
In our present case, systemic spread of the tumor was detected within the first 
month. Thus, even though we administered intensive chemotherapy soon after the 
diagnosis, the patient died 5 months after her first visit to our clinic. Therefore, 
dermatologists need to be familiar with the clinical features of BPDCN to diagnose this 
disease immediately. 
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Fig. 1. Multiple areas of disseminated, elastic hard nodules with multicentric purpura on the patient’s 
scalp. 
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Fig. 2. Atypical large lymphocytes densely infiltrated through the upper dermis to subcutaneous tissue 
with minimal involvement of the overlying epidermis (a; H&E staining, original magnification ×50). 
Median-sized monomorphous cells with irregular nuclei were infiltrating (b; H&E staining, original 
magnification ×400). Immunohistochemical staining for CD4 (c) and CD56 (d; original magnification ×50). 
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